295 related articles for article (PubMed ID: 20055714)
1. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.
Köhler R; Kaistha BP; Wulff H
Expert Opin Ther Targets; 2010 Feb; 14(2):143-55. PubMed ID: 20055714
[TBL] [Abstract][Full Text] [Related]
2. Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery.
Grgic I; Kaistha BP; Hoyer J; Köhler R
Br J Pharmacol; 2009 Jun; 157(4):509-26. PubMed ID: 19302590
[TBL] [Abstract][Full Text] [Related]
3. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
Wulff H; Kolski-Andreaco A; Sankaranarayanan A; Sabatier JM; Shakkottai V
Curr Med Chem; 2007; 14(13):1437-57. PubMed ID: 17584055
[TBL] [Abstract][Full Text] [Related]
4. Endothelial dysfunction and blood pressure alterations in K+-channel transgenic mice.
Köhler R; Ruth P
Pflugers Arch; 2010 May; 459(6):969-76. PubMed ID: 20349244
[TBL] [Abstract][Full Text] [Related]
5. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Sankaranarayanan A; Raman G; Busch C; Schultz T; Zimin PI; Hoyer J; Köhler R; Wulff H
Mol Pharmacol; 2009 Feb; 75(2):281-95. PubMed ID: 18955585
[TBL] [Abstract][Full Text] [Related]
6. Endothelial Small- and Intermediate-Conductance K Channels and Endothelium-Dependent Hyperpolarization as Drug Targets in Cardiovascular Disease.
Köhler R; Oliván-Viguera A; Wulff H
Adv Pharmacol; 2016; 77():65-104. PubMed ID: 27451095
[TBL] [Abstract][Full Text] [Related]
7. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.
Hasenau AL; Nielsen G; Morisseau C; Hammock BD; Wulff H; Köhler R
Acta Physiol (Oxf); 2011 Sep; 203(1):117-26. PubMed ID: 21362152
[TBL] [Abstract][Full Text] [Related]
8. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel.
Si H; Heyken WT; Wölfle SE; Tysiac M; Schubert R; Grgic I; Vilianovich L; Giebing G; Maier T; Gross V; Bader M; de Wit C; Hoyer J; Köhler R
Circ Res; 2006 Sep; 99(5):537-44. PubMed ID: 16873714
[TBL] [Abstract][Full Text] [Related]
9. The intermediate-conductance Ca2+ -activated K+ channel (KCa3.1) in vascular disease.
Tharp DL; Bowles DK
Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):1-11. PubMed ID: 19149539
[TBL] [Abstract][Full Text] [Related]
10. Endothelial K
Li JJ; Zhao XY; Wang Y; Xu R; Di XH; Zhang Y; Yang H; Han MZ; Bai RY; Xie L; Pang ZD; Zhang X; Zhang J; Du XJ; Deng XL; Zhang Y; Xie W
Arterioscler Thromb Vasc Biol; 2023 May; 43(5):726-738. PubMed ID: 36951065
[TBL] [Abstract][Full Text] [Related]
11. Single-nucleotide polymorphisms in vascular Ca2+-activated K+-channel genes and cardiovascular disease.
Köhler R
Pflugers Arch; 2010 Jul; 460(2):343-51. PubMed ID: 20043229
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
Brown BM; Shim H; Christophersen P; Wulff H
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():219-240. PubMed ID: 31337271
[TBL] [Abstract][Full Text] [Related]
13. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.
Wulff H; Köhler R
J Cardiovasc Pharmacol; 2013 Feb; 61(2):102-12. PubMed ID: 23107876
[TBL] [Abstract][Full Text] [Related]
14. Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice.
Radtke J; Schmidt K; Wulff H; Köhler R; de Wit C
Br J Pharmacol; 2013 Sep; 170(2):293-303. PubMed ID: 23734697
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs.
Damkjaer M; Nielsen G; Bodendiek S; Staehr M; Gramsbergen JB; de Wit C; Jensen BL; Simonsen U; Bie P; Wulff H; Köhler R
Br J Pharmacol; 2012 Jan; 165(1):223-34. PubMed ID: 21699504
[TBL] [Abstract][Full Text] [Related]
16. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?
Félétou M
Br J Pharmacol; 2009 Feb; 156(4):545-62. PubMed ID: 19187341
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic targeting of endothelial Ca
Mathew John C; Khaddaj Mallat R; George G; Kim T; Mishra RC; Braun AP
Channels (Austin); 2018 Jan; 12(1):126-136. PubMed ID: 29577810
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of
Kloza M; Baranowska-Kuczko M; Toczek M; Kusaczuk M; Sadowska O; Kasacka I; Kozłowska H
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450834
[TBL] [Abstract][Full Text] [Related]
19. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension.
Brähler S; Kaistha A; Schmidt VJ; Wölfle SE; Busch C; Kaistha BP; Kacik M; Hasenau AL; Grgic I; Si H; Bond CT; Adelman JP; Wulff H; de Wit C; Hoyer J; Köhler R
Circulation; 2009 May; 119(17):2323-32. PubMed ID: 19380617
[TBL] [Abstract][Full Text] [Related]
20. The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on K
Kloza M; Baranowska-Kuczko M; Malinowska B; Karpińska O; Harasim-Symbor E; Kasacka I; Kozłowska H
Vascul Pharmacol; 2017 Dec; 99():65-73. PubMed ID: 29038048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
